What is the Link Between Pharmacovigilance and Building Confidence Around COVID-19 Vaccines? Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, the featured speakers will discuss what the main hesitancy factors are against receiving a COVID vaccine and how this closely relates to modern pharmacovigilance & safety operations. Attendees will also learn about the activities and resources ICON is deploying to build confidence in COVID-19 vaccines and why these activities are essential to resolve the public health crisis.

At the end of 2020, between 37 and 44 percent of Americans stated that they would not accept a COVID-19 vaccine, whatever the cost.

In 2019, the WHO identified vaccine hesitancy as one of the top ten global health threats. At the end of 2020, between 37 and 44 percent of Americans stated that they would not accept a COVID-19 vaccine, whatever the cost. The exceptionally fast pace of development, the seemingly new mRNA technology of some of the vaccines, the accelerated approval process and the mistrustful attitude of the population have created a unique regulatory setting where pharmacovigilance and safety have become cornerstone. Of note, the rates of (re-) infection post-vaccine do not appear in any of the risk management plans (RMP) of vaccine makers.

ICON can provide differentiated service in ensuring vaccine safety through:

  • Provision of safety monitoring after approval, including:
  • Post-marketed signal detection utilizing MAH specific data and data from public databases, literature
  • Tracking of signals and Risk Minimization Measures
  • Facilitate drafting and submission of aggregate safety reports
  • Post-authorization safety studies conducted by the vaccines’ manufacturers, as well as other longitudinal observational studies
  • Results of an in-house study on rates of COVID (re-)infections post-vaccine amongst patients with a critical disease

Using modern technologies and methods is paramount in fulfilling the complete lifecycle of these vaccines and building confidence in our healthcare systems.

Join experts from ICON Plc, Florent Richy, Director, Pharmacovigilance & Patient Safety; Bettina Rillmann, Director, Operations, Real World Solutions; and Robina Azam, Director, Patient Safety, Pharmacovigilance & Patient Safety, in a live webinar on Monday, November 29, 2021 at 10am EST (3pm GMT/UK).

For more information, or to register for this event, visit What is the Link Between Pharmacovigilance and Building Confidence Around COVID-19 Vaccines?

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ayesha Rashid
Xtalks
+1 (416) 977-6555 x 272
Email >
Visit website